355 results on '"Hartleb, Marek"'
Search Results
102. Liver Injury Induced by High-Dose Methylprednisolone Therapy: A Case Report and Brief Review of the Literature
- Author
-
Gutkowski, Krzysztof, primary, Chwist, Alina, additional, and Hartleb, Marek, additional
- Published
- 2011
- Full Text
- View/download PDF
103. Nodular regenerative hyperplasia: Evolving concepts on underdiagnosed cause of portal hypertension
- Author
-
Hartleb, Marek, primary
- Published
- 2011
- Full Text
- View/download PDF
104. Granulomatous diseases of the liver
- Author
-
Gutkowski, Krzysztof, primary, Hartleb, Marek, additional, and Gutkowska, Dorota, additional
- Published
- 2011
- Full Text
- View/download PDF
105. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD)
- Author
-
Raszeja-Wyszomirska, Joanna, primary, Szymanik, Barbara, additional, Ławniczak, Małgorzata, additional, Kajor, Maciej, additional, Chwist, Alina, additional, Milkiewicz, Piotr, additional, and Hartleb, Marek, additional
- Published
- 2010
- Full Text
- View/download PDF
106. Serum chemerin and vaspin in non-alcoholic fatty liver disease
- Author
-
Kukla, Michal, primary, Zwirska-Korczala, Krystyna, additional, Hartleb, Marek, additional, Waluga, Marek, additional, Chwist, Alina, additional, Kajor, Maciej, additional, Ciupinska-Kajor, Monika, additional, Berdowska, Agnieszka, additional, Wozniak-Grygiel, Elzbieta, additional, and Buldak, Rafal, additional
- Published
- 2010
- Full Text
- View/download PDF
107. Serum C-reactive protein level does not correlate with Crohn’s Disease Activity Index
- Author
-
Kohut, Maciej, primary, Kozioł, Katarzyna, additional, Olek, Emilia, additional, Koclęga, Anna, additional, and Hartleb, Marek, additional
- Published
- 2010
- Full Text
- View/download PDF
108. Hepatocellular carcinoma – diagnostic dilemmas
- Author
-
Gutkowski, Krzysztof, primary, Hartleb, Marek, additional, and Kajor, Maciej, additional
- Published
- 2010
- Full Text
- View/download PDF
109. Comment on “Hepatitis C Virus-Specific Th17 Cells Are Suppressed by Virus-Induced TGF-β”
- Author
-
Gutkowski, Krzysztof, primary and Hartleb, Marek, additional
- Published
- 2009
- Full Text
- View/download PDF
110. Pernicious anemia during peginterferon-αα2b plus ribavirin therapy for chronic hepatitis C
- Author
-
Musialik, Joanna, primary, Petelenz, Michał, additional, -Fajfrowska, Barbara Błoñska, additional, and Hartleb, Marek, additional
- Published
- 2009
- Full Text
- View/download PDF
111. T1870 Critical Flicker Frequency Analysis in Patients with Primary Biliary Cirrhosis
- Author
-
Wunsch, Ewa, primary, Post, Michal, additional, Gutkowski, Krzysztof, additional, Marlicz, Wojciech M., additional, Hartleb, Marek, additional, and Milkiewicz, Piotr, additional
- Published
- 2009
- Full Text
- View/download PDF
112. Increasing Prevalence of Barrett's Esophagus with Relatively Low Risk of Neoplasia - Three-Year Prospective Cohort Study from Central European Country
- Author
-
Marek, Tomasz A., primary, Mularczyk, Anna, additional, Szczepanska, Anna J., additional, Palen, Piotr, additional, Dziurkowska-Marek, Anna, additional, Kajor, Maciej, additional, and Hartleb, Marek, additional
- Published
- 2009
- Full Text
- View/download PDF
113. S.39. Serum Levels of IL-17 and Its Activators in Patients with Autoimmune Hepatitis are Nondependent on Histological Activiy within the Liver- Preliminary Results
- Author
-
Gutkowski, Krzysztof, primary, Kacperek-Hartleb, Teresa, additional, Kajor, Maciej, additional, Mazur, Wlodzimierz, additional, Boryczka, Grzegorz, additional, and Hartleb, Marek, additional
- Published
- 2009
- Full Text
- View/download PDF
114. Composite neuroendocrine and adenomatous carcinoma of the papilla of Vater
- Author
-
Musialik, Joanna A, primary, Kohut, Maciej J, additional, Marek, Tomasz, additional, Wodołażski, Anatol, additional, and Hartleb, Marek, additional
- Published
- 2009
- Full Text
- View/download PDF
115. Role of sympathetic cardiovascular tone in control of arterial pressure in rats with cirrhosis
- Author
-
Kirstetter, Philippe, primary, Moreau, Richard, additional, Soupison, Thierry, additional, Cailmail, Stéphane, additional, Hartleb, Marek, additional, and Lebrec, Didier, additional
- Published
- 2008
- Full Text
- View/download PDF
116. Cardiovascular status after postural change in compensated cirrhosis: an argument for vasodilatory concept
- Author
-
Hartleb, Marek, primary, Rudzki, Krystian, additional, Karpel, Ewa, additional, Becker, Alina, additional, Waluga, Marek, additional, Boldys, Hubert, additional, Nowak, Andrzej, additional, and Nowak, Stanislaw, additional
- Published
- 2008
- Full Text
- View/download PDF
117. Haemobilia causing acute pancreatitis after percutaneous liver biopsy
- Author
-
Nowak, Andrzej, primary, Hartleb, Marek, additional, Kohut, Maciej, additional, Nowakowska-Duława, Ewa, additional, and Pilch-Kowalczyk, Joanna, additional
- Published
- 2005
- Full Text
- View/download PDF
118. Autoimmune LKM1 hepatitis presenting in the form of recurrent acute episodes
- Author
-
Hartleb, Marek, primary, Nowak, Andrzej, additional, Kajor, Maciej, additional, and Wlaszczuk, Pawel, additional
- Published
- 2002
- Full Text
- View/download PDF
119. Severe hepatic involvement in visceral larva migrans
- Author
-
Hartleb, Marek, primary and Januszewski, Krzysztof, additional
- Published
- 2001
- Full Text
- View/download PDF
120. Esophageal squamous-cell papillomatosis complicated by carcinoma
- Author
-
Waluga, Marek, primary, Hartleb, Marek, additional, Sliwinski, Zbigniew K., additional, Romanczyk, Tomasz, additional, and Wodolazki, A., additional
- Published
- 2000
- Full Text
- View/download PDF
121. Hepatic Chemerin and Chemokine-Like Receptor 1 Expression in Patients with Chronic Hepatitis C.
- Author
-
Kukla, Michał, Adamek, Brygida, Waluga, Marek, Zalewska-Ziob, Marzena, Kasperczyk, Janusz, Gabriel, Andrzej, Mazur, Włodzimierz, Sobala-Szczygieł, Barbara, Bułdak, Rafał J., Zajęcki, Wojciech, Kępa, Lucjan, Ziora, Katarzyna, Żwirska-Korczala, Krystyna, Wiczkowski, Andrzej, and Hartleb, Marek
- Abstract
Introduction. Chemerin seems to be involved in pathogenesis of chronic hepatitis C (CHC). Hepatic expressions of chemerin and its receptor, chemokine receptor-like 1 (CMKLR1), in CHC have not been studied so far. Aim. To evaluate chemerin and CMKLR1 hepatic expression togetherwith serum chemerin concentration in CHC patients and to assess their relationship with metabolic and histopathological abnormalities. Methods.The study included 63 nonobese CHC patients. Transcription of chemerin and CMKLR1 was assessed by quantitative real-time PCR,while serumchemerin was assessed by enzyme-linked immunosorbent assay. Results. Expression of chemerin and CMKLR1 was present in the liver of all CHC patients regardless of sex or age.This expression was not associated with necroinflammatory activity and steatosis grade, fibrosis stage, and metabolic abnormalities.There was a negative association between serum chemerin and chemerin hepatic expression (r = (-0.41), P = 0.006). Conclusion. The study for the first time confirmed a marked expression of chemerin and CMKLR1 in the liver of CHC patients. The study was performed using the homogenates of human liver tissue, so it is not possible to define whether hepatocytes or other cell types which are abundantly represented in the liver constitute the main source of chemerin and CMKLR1 mRNA. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
122. Acute Cholestatic Hepatitis Associated With Pravastatin
- Author
-
Hartleb, Marek, primary, Rymarczyk, Grzegorz, additional, and Januszewski, Krzysztof, additional
- Published
- 1999
- Full Text
- View/download PDF
123. Hepatic pseudotumour — Caudate lobe sparing in fatty liver
- Author
-
Hartleb, Marek, primary, Nowak, Andrzej, additional, and Scieszka, Joanna, additional
- Published
- 1995
- Full Text
- View/download PDF
124. Lack of vascular hyporesponsiveness to the L-type calcium channel activator, Bay K 8644, in rats with cirrhosis
- Author
-
Hartleb, Marek, primary, Moreau, Richard, additional, Gaudin, Christophe, additional, and Lebrec, Didier, additional
- Published
- 1995
- Full Text
- View/download PDF
125. Effect of propranolol on portosystemic collateral circulation estimated by per-rectal portal scintigraphy with technietium-99m pertechnetate
- Author
-
Bołdys, Huberg, primary, Hartleb, Marek, additional, Rudzki, Krystian, additional, Nowak, Andrzej, additional, and Nowak, Stanisław, additional
- Published
- 1995
- Full Text
- View/download PDF
126. Vascular hyporesponsiveness to endothelin 1 in rats with cirrhosis
- Author
-
Hartleb, Marek, primary, Moreau, Richard, additional, Cailmail, Stephane, additional, Gaudin, Christophe, additional, and Lebrec, Didier, additional
- Published
- 1994
- Full Text
- View/download PDF
127. Blunted systemic, splanchnic, and renal hemodynamic responses to atrial natriuretic peptide in rats with cirrhosis
- Author
-
Ohsuga, Masaru, primary, Moreau, Richard, additional, Hartleb, Marek, additional, Komeichi, Hirokazu, additional, and Lebrec, Didier, additional
- Published
- 1994
- Full Text
- View/download PDF
128. Segmental mean transit times of 99m technetium within central vascular space in liver cirrhosis
- Author
-
Hartleb, Marek, primary and Rudzki, Krystian, additional
- Published
- 1992
- Full Text
- View/download PDF
129. Validation of the BARD scoring system in Polishpatients with nonalcoholic fatty liver disease(NAFLD).
- Author
-
Raszeja-Wyszomirska, Joanna, Szymanik, Barbara, Lawniczak, Malgorzata, Kajor, Maciej, Chwist, Alina, Milkiewicz, Piotr, and Hartleb, Marek
- Subjects
FATTY liver ,LIVER diseases ,FATTY degeneration ,CIRRHOSIS of the liver ,PATIENTS - Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) includes a wide spectrum of liver diseases, ranging from pure steatosis to nonalcoholic steatohepatitis (NASH), and eventually to liver cirrhosis with its complications. Identifying advanced fibrosis in patients is crucial to evaluating prognosis and possible therapeutic intervention. A novel, simple, and highly accurate scoring system called BARD, which identifies patients with NAFLD and without significant fibrosis, has been recently introduced and validated in North America..The aim of this study is to validate the BARD scoring system in a Polish cohort with NAFLD. Methods: A group of 104 Caucasians with biopsy-proven NAFLD were included in this study. Fibrosis in liver biopsies was evaluated according to the Histological Scoring System for Nonalcoholic Fatty Liver Disease. The BARD scoring system was assessed according to Harrison et al.: BMI ≥ 28 = 1 point, AST/ALT ratio (AAR) ≥ 0.8 = 2 points, type 2 diabetes mellitus = 1point. Results: Age over 50 and AAR over 0.8 showed, respectively, a moderate and strong association with advanced fibrosis. A BARD score of 2-4 points was associated with F3 or F4 stages of fibrosis with an odds ratio of 17.333 (95% Cl; 3,639 - 82.558) and negative predictive value of 97%. Conclusion: Our results demonstrate that the BARD scoring system has value in the non-invasive diagnosis of advanced fibrosis in NAFLD patients. The vast majority of patients with NAFLD would avoid liver biopsy if BARD was broadly introduced into the clinic. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
130. Immunologicnzne i genetyczne aspekty autoimmunologicznego zapalenia wątroby.
- Author
-
Gutkowski, Krzystof and Hartleb, Marek
- Subjects
- *
AUTOIMMUNE diseases , *HEPATITIS , *LIVER diseases , *AUTOANTIBODIES , *IMMUNOGLOBULINS , *MEDICAL research - Abstract
Autoimmune hepatitis (AIH) is a chronic necro-inflammatory liver disease of poorly defined etiology, characterized by elevated levels of amino- transferases, raised concentration of immunoglobulin class G and presence of circulating autoantibodies. In view of recent studies, autoantibodies directed against asialoglycoprotein receptor (ASGPR), liver cytosol type-1 antigen (LC-1), soluble liver/liver-pancreas antigen (SLA/LP) and actin have prognostic significance in AIH patients. Molecular mimicry between host and viral antigens is the most plausible mechanism for initiating immunological cascade in AIH patients. Some HLA genotypes are closely associated with the risk of AIH development, clinical course and outcome. In this review we discuss immunogenetic aspects of AIH with evaluation of its importance in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2008
131. LETTERS TO THE EDITOR Hepatic Arterial Dot Signs In Isolated Small Duct Primary Sclerosing Cholangitis.
- Author
-
Hartleb, Marek, Pilch-Kowalczyk, Joanna, Cholewka, Andrzej, Kajor, Maciej, and Blaszczyńska, Malgorzata
- Subjects
- *
LETTERS to the editor , *BILE ducts - Abstract
Presents a letter to the editor about primary sclerosing cholangitis which is limited to interlobular and segmental branches of the bile-duct system.
- Published
- 2004
- Full Text
- View/download PDF
132. Su.112. Expression of Cd38 and Cd5 Surface Markers On Peripheral Blood B Lymphocytes (Cd19+) in Patients with Autoimmune Hepatitis; Influence of Prednisone and Azathioprine Five Months Therapy
- Author
-
Gutkowski, Krzysztof, Hartleb, Marek, and Pluta, Andrzej
- Published
- 2006
- Full Text
- View/download PDF
133. Wilson's Disease Presenting in Sisters as Fulminant Hepatitis with Hemolytic Episodes.
- Author
-
Hartleb, Marek, Zahorska-Markiewicz, Barbara, and Ciesielski, Artur
- Subjects
HEPATOLENTICULAR degeneration ,HEPATITIS ,HEMOLYSIS & hemolysins ,DEATH (Biology) ,FAMILIAL diseases - Abstract
Wilson's disease presenting as fulminant hepatic failure is a rare and poorly recognized disorder. When ophthalmic and neurologic signs are missing and liver biopsy cannot be performed the patients may not be diagnosed and treated specifically. An acute hemolysis only occasionally occurs in Wilson's disease hut is considered a distinctive feature in the form of fulminant hepatitis. Two homozygous sisters suffering fatal Wilsonian fulminant hepatitis with hemolytic episodes are presented. Failure or delay in diagnosis seems to be responsible for high mortality in this form of Wilson's disease. Diagnostic value of familial history and laboratory results is discussed. [ABSTRACT FROM AUTHOR]
- Published
- 1987
134. Autoimmune LKM 1 hepatitis presenting in the form of recurrent acute episodes
- Author
-
Hartleb, Marek, Nowak, Andrzej, Kajor, Maciej, and Właszczuk, Paweł
- Published
- 2002
- Full Text
- View/download PDF
135. Pernicious anemia during peginterferon-alpha2b plus ribavirin therapy for chronic hepatitis C.
- Author
-
Musialik J, Petelenz M, Bloñska-Fajfrowska B, Hartleb M, Musialik, Joanna, Petelenz, Michał, Błoñska-Fajfrowska, Barbara, and Hartleb, Marek
- Published
- 2009
- Full Text
- View/download PDF
136. Autoimmune LKM1 hepatitis presenting in the form of recurrent acute episodes
- Author
-
Hartleb, Marek, Nowak, Andrzej, Kajor, Maciej, and Wlaszczuk, Pawel
- Published
- 2002
- Full Text
- View/download PDF
137. Do Thyroid Hormones Promote Hepatotoxicity to Acetaminophen?
- Author
-
Hartleb, Marek
- Subjects
LETTERS to the editor ,THYROID hormones - Abstract
Presents a letter to the editor about a study on the role of thyroid hormones in promoting hepatotoxicity to acetaminophen.
- Published
- 1994
138. Severe Jaundice with Destructive Cholangitis after Administration of Methyltestosterone.
- Author
-
Hartleb, Marek and Nowak, Andrzej
- Subjects
LETTERS to the editor ,TESTOSTERONE - Abstract
Presents a letter to the editor about severe jaundice with destructive cholangitis after the administration of methyltestosterone.
- Published
- 1990
139. Fulminant Wilsonian Hepatitis.
- Author
-
Willson, Richard A. and Hartleb, Marek
- Subjects
LETTERS to the editor ,HEPATITIS - Abstract
Presents a letter to the editor about fulminant Wilsonian hepatitis.
- Published
- 1988
140. Liver phenotypes in PCOS: Analysis of exogenous and inherited risk factors for liver injury in two European cohorts.
- Author
-
Smyk, Wiktor, Papapostoli, Ifigeneia, Żorniak, Michał, Sklavounos, Panagiotis, Blukacz, Łukasz, Madej, Paweł, Koutsou, Andreani, Weber, Susanne N., Friesenhahn‐Ochs, Bettina, Cebula, Maciej, Bosowska, Joanna, Solomayer, Erich‐Franz, Hartleb, Marek, Milkiewicz, Piotr, Lammert, Frank, Stokes, Caroline S., and Krawczyk, Marcin
- Subjects
- *
INJURY risk factors , *FATTY liver , *POLYCYSTIC ovary syndrome , *HEPATIC fibrosis , *DISEASE progression , *LIVER - Abstract
Background & Aims: Fatty liver disease (FLD) is common in women with polycystic ovary syndrome (PCOS). Here, we use non‐invasive tests to quantify liver injury in women with PCOS and analyse whether FLD‐associated genetic variants contribute to liver phenotypes in PCOS. Methods: Prospectively, we recruited women with PCOS and controls at two university centres in Germany and Poland. Alcohol abuse was regarded as an exclusion criterion. Genotyping of variants associated with FLD was performed using TaqMan assays. Liver stiffness measurements (LSM), controlled attenuation parameters (CAP) and non‐invasive HSI, FLI, FIB‐4 scores were determined to assess hepatic steatosis and fibrosis. Results: A total of 42 German (age range 18–53 years) and 143 Polish (age range 18–40 years) women with PCOS, as well as 245 German and 289 Polish controls were recruited. In contrast to Polish patients, Germans were older, presented with more severe metabolic profiles and had significantly higher LSM (median 5.9 kPa vs. 3.8 kPa). In the German cohort, carriers of the PNPLA3 p.I148M risk variant had an increased LSM (p =.01). In the Polish cohort, the minor MTARC1 allele was linked with significantly lower serum aminotransferases activities, whereas the HSD17B13 polymorphism was associated with lower concentrations of 17‐OH progesterone, total testosterone, and androstenedione (all p <.05). Conclusions: FLD is common in women with PCOS. Its extent is modulated by both genetic and metabolic risk factors. Genotyping of variants associated with FLD might help to stratify the risk of liver disease progression in women suffering from PCOS. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
141. Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology.
- Author
-
Eder, Piotr, Łodyga, Michał, Gawron-Kiszka, Magdalena, Dobrowolska, Agnieszka, Gonciarz, Maciej, Hartleb, Marek, Kłopocka, Maria, Małecka-Wojciesko, Ewa, Radwan, Piotr, Reguła, Jarosław, Zagórowicz, Edyta, Banasiewicz, Tomasz, Durlik, Marek, and Rydzewska, Grażyna
- Subjects
- *
ULCERATIVE colitis , *GASTROENTEROLOGY , *LIKERT scale , *CONSULTANTS - Abstract
This paper is an update of the diagnostic and therapeutic recommendations of the National Consultant for Gastroenterology and the Polish Society of Gastroenterology from 2013. It contains 49 recommendations for the diagnosis and treatment, both pharmacological and surgical, of ulcerative colitis in adults. The guidelines were developed by a group of experts appointed by the Polish Society of Gastroenterology and the National Consultant in the field of Gastroenterology. The methodology related to the GRADE methodology was used to assess the quality of available evidence and the strength of therapeutic recommendations. The degree of expert support for the proposed statements was assessed on a 6-point Likert scale. Voting results, together with comments, are included with each statement. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
142. Treatment of pruritus with Prometheus dialysis and absorption system in a patient with benign recurrent intrahepatic cholestasis.
- Author
-
Ołdakowska‐Jedynak, Urszula, Jankowska, Irena, Hartleb, Marek, Jirsa, Milan, Pawłowska, Joanna, Czubkowski, Piotr, and Krawczyk, Marek
- Subjects
- *
ITCHING , *HEMODIALYSIS , *ABSORPTION (Physiology) , *CHOLESTASIS , *DISEASE relapse , *LIVER disease treatment , *JAUNDICE , *THERAPEUTICS - Abstract
Benign recurrent intrahepatic cholestasis ( BRIC) is an autosomal recessive liver disorder characterized by recurrent episodes of jaundice and itching. Episodes of cholestasis last variously from 1 week to several months, may start at any age and usually resolve spontaneously. No effective treatment has been found as yet. We report a case of genetically proven BRIC in a male patient who developed three episodes of pruritus and jaundice at the age of 14, 16 and 19 years. During the third episode, he did not respond to pharmacological medical therapy, and fractionated plasma separation and absorption ( FPSA, Prometheus) was performed to manage intractable pruritus. The treatment immediately alleviated pruritus, lowered serum bilirubin concentration and induced sustained remission in the 5-year follow up. FPSA seems to be a safe and effective way of treatment for BRIC in patients with severe pruritus and prolonged jaundice. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
143. Composite detection rate as an upper gastrointestinal endoscopy quality measure correlating with detection of neoplasia.
- Author
-
Romańczyk, Marcin, Ostrowski, Bartosz, Marek, Tomasz, Romańczyk, Tomasz, Błaszczyńska, Małgorzata, Budzyń, Krzysztof, Bugajski, Maciej, Koziej, Mateusz, Kajor, Maciej, Januszewski, Krzysztof, Zajęcki, Wojciech, Waluga, Marek, and Hartleb, Marek
- Subjects
- *
ENDOSCOPY , *GENDER , *UNIVERSITY hospitals , *DIGESTIVE system endoscopic surgery , *POLYPS - Abstract
Background: Esophagogastroduodenoscopy (EGD) is commonly used diagnostic method with no widely accepted quality measure. We assessed quality indicator—composite detection rate (CDR)—consisting of detection of at least one of the following: cervical inlet patch, gastric polyp and post-ulcer duodenal bulb deformation. The aim of the study was to validate CDR according to detection rate of upper gastrointestinal neoplasms (UGN). Methods: It was a multicenter, prospective, observational study conducted from January 2019 to October 2019. The endoscopic reports from 2896 symptomatic patients who underwent diagnostic EGD were analyzed. The EGDs were performed in three endoscopy units located in tertiary university hospital, private outpatient clinic and local hospital. Results: 64 UGNs were detected. The mean CDR was 21.9%. The CDR correlated with UGN detection rate (R = 0.49, p = 0.045). Based on CDR quartiles, operators were divided into group 1 with CDR < 10%, group 2 with CDR 10–17%, group 3 with CDR 17.1–26%, and group 4 with CDR > 26%. Detection rate of UGN was significantly higher in the group 4 in comparison to group 1 (OR 4.4; 95% CI 2.2 − 9.0). In the multivariate regression model, patient age, male gender and operator's CDR > 26% were independent risk factors of UGN detection (OR 1.03; 95% CI 1.01 − 1.05, OR 2; 95% CI 1.2 − 3.5, and OR 5.7 95% CI 1.5 − 22.3, respectively). Conclusions: The CDR is associated with the detection of upper gastrointestinal neoplasms. This parameter may be a useful quality measure of EGD to be applied in general setting. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
144. Influence of narrow-band imaging (NBI) and enhanced operator's attention during esophagus inspection on cervical inlet patches detection.
- Author
-
Romańczyk, Marcin, Romańczyk, Tomasz, Lesińska, Magdalena, Romańczyk, Agnieszka, Hartleb, Marek, and Waluga, Marek
- Subjects
- *
ESOPHAGUS , *GASTRIC mucosa , *INLETS , *ATTENTION , *REGRESSION analysis - Abstract
Heterotopic gastric mucosa in the upper esophagus (cervical inlet patches - CIP) may be easily missed during esophagogastroduodenoscopy (EGD) due to low awareness of this usually, but not invariably, benign lesion. Narrow-band imaging (NBI) emphasizes contrast between normal esophageal mucosa and CIP. The purpose of this study was to investigate how NBI use and enhanced attention of operator during inspection of upper esophagus impacts cervical inlet patch detection rate (CIPDR). This is a prospective, randomized study in which we enrolled 1000 patients, qualified for diagnostic EGD. The trial was divided into two parts; the first, when 6 operators performed EGD with standard attention (SA), and the second, when the same operators were asked to step up with attention at CIP (enhanced attention - EA). In both parts of the study, patients were randomized to NBI and white light endoscopy (WLE) in 1:1 ratio. The study is registered in ClinicalTrials.gov (No. NCT03015571). Differences in CIPDR between WLE and NBI in SA and EA were not statistically different (5.6% vs 7.6%; p = 0.3, and 7.6% vs 11.6%; p = 0.1, respectively). In multivariate regression analysis, the only factors improving CIPDR were NBI with EA (NBI EA , OR 3.31; 95%CI 1.57–6.98; p = 0.003) and sedation (OR 1.97; 95%CI 1.27–3.05; p = 0.002). The use of NBI combined with EA significantly improves CIPDR. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
145. Correction to: Composite detection rate as an upper gastrointestinal endoscopy quality measure correlating with detection of neoplasia.
- Author
-
Romańczyk, Marcin, Ostrowski, Bartosz, Marek, Tomasz, Romańczyk, Tomasz, Błaszczyńska, Małgorzata, Budzyń, Krzysztof, Bugajski, Maciej, Koziej, Mateusz, Kajor, Maciej, Januszewski, Krzysztof, Zajęcki, Wojciech, Waluga, Marek, and Hartleb, Marek
- Published
- 2022
- Full Text
- View/download PDF
146. Quality of Life in Patients with Irritable Bowel Syndrome (IBS), Assessed Using the IBS-Quality of Life (IBS-QOL) Measure After 4 and 8 Weeks of Treatment with Mebeverine Hydrochloride or Pinaverium Bromide: Results of an International Prospective Observational Cohort Study in Poland, Egypt, Mexico and China
- Author
-
Hou, Xiaohua, Chen, Shengliang, Zhang, Yali, Sha, Weihong, Yu, Xiaofeng, Elsawah, Hesham, Afifi, Afifi, El-Khayat, Hisham, Nouh, Alaa, Hassan, Mohamed, Fatah, Ayman, Rucker Joerg, Isabel, Sánchez Núñez, Juan, Osthoff Rueda, Rodolfo, Jurkowska, Grazyna, Walczak, Michal, Malecka-Panas, Ewa, Linke, Krzysztof, Hartleb, Marek, and Janssen-van Solingen, Gwendolyn
- Subjects
- *
IRRITABLE colon treatment , *QUALITY of life , *IRRITABLE colon , *BROMIDES , *STATISTICAL significance , *PATIENTS - Abstract
Background and Objective: Irritable Bowel Syndrome (IBS) has a substantial impact on health-related quality of life (HR-QoL) but high-quality data pre- and post-treatment using the IBS-Quality of Life (IBS-QOL) measure are limited. The objective of this study was to evaluate the changes from baseline of the IBS-QOL scores, symptom scores and health economic data in IBS patients, after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide. Methods: This was a prospective observational cohort study in patients with IBS, diagnosed using the Rome III criteria in four countries (Poland, Egypt, Mexico and China). Results: A total of 607 patients were enrolled. At baseline, the IBS-QOL total scores were 52.0 in Poland, 48.9 in Egypt, 51.9 in Mexico, 76.4 in China and 56.4 overall. Increases in IBS-QOL total score were statistically significant at Weeks 4 and 8 overall and in each country (overall: 11.8 at Week 4, 24.3 at Week 8; p < 0.001). Improvements were shown in all IBS-QOL subscales and scores. Symptoms and health economic outcomes were improved. Furthermore, the favourable safety profile of these treatments was confirmed in this study. Conclusions: This study demonstrated that IBS patients have a substantially reduced HR-QoL and that treatment with mebeverine hydrochloride or pinaverium bromide improved HR-QoL. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
147. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- Author
-
Zobair M Younossi, Vlad Ratziu, Rohit Loomba, Mary Rinella, Quentin M Anstee, Zachary Goodman, Pierre Bedossa, Andreas Geier, Susanne Beckebaum, Philip N Newsome, David Sheridan, Muhammad Y Sheikh, James Trotter, Whitfield Knapple, Eric Lawitz, Manal F Abdelmalek, Kris V Kowdley, Aldo J Montano-Loza, Jerome Boursier, Philippe Mathurin, Elisabetta Bugianesi, Giuseppe Mazzella, Antonio Olveira, Helena Cortez-Pinto, Isabel Graupera, David Orr, Lise Lotte Gluud, Jean-Francois Dufour, David Shapiro, Jason Campagna, Luna Zaru, Leigh MacConell, Reshma Shringarpure, Stephen Harrison, Arun J Sanyal, Manal Abdelmalek, Gary Abrams, Humberto Aguilar, Aijaz Ahmed, Elmar Aigner, Guruprasad Aithal, Aftab Ala, William Alazawi, Agustin Albillos, Michael Allison, Sfa Al-Shamma, Raul Andrade, Pietro Andreone, Mario Angelico, Victor Ankoma-Sey, Quentin Anstee, Rodolphe Anty, Victor Araya, Juan Ignacio Arenas Ruiz, Perttu Arkkila, Marty Arora, Tarik Asselah, Jennifer Au, Oyekoya Ayonrinde, Robert James Bailey, Maya Balakrishnan, Kiran Bambha, Meena Bansal, Sidney Barritt, John Bate, Jorge Beato, Jaideep Behari, Pablo Bellot, Ziv Ben Ari, Michael Bennett, Marina Berenguer, Benedetta Terziroli Beretta-Piccoli, Thomas Berg, Maurizio Bonacini, Lucia Bonet, Brian Borg, Marc Bourliere, William Bowman, David Bradley, Marija Brankovic, Marius Braun, Jean-Pierre Bronowicki, Savino Bruno, Cindy Cai, Amy Calderon, José Luis Calleja Panero, Elizabeth Carey, Michal Carmiel, Jose Antonio Carrión, Matthew Cave, Cristina Chagas, Tawfik Chami, Alan Chang, Allan Coates, Jeremy Cobbold, Charlote Costentin, Kathleen Corey, Lynsey Corless, Javier Crespo, Oscar Cruz Pereira, Victor de Ledinghen, Andrew deLemos, Moises Diago, Mamie Dong, Jean-François Dufour, Predrag Dugalic, Winston Dunn, Magby Elkhashab, Michael Epstein, Maria Desamparados Escudero-Garcia, Ohad Etzion, Larry Evans, Robert Falcone, Conrado Fernandez, Jose Ferreira, Scott Fink, Kevin Finnegan, Roberto Firpi-Morell, Annarosa Floreani, Thierry Fontanges, Ryan Ford, Ewan Forrest, Andrew Fowell, Anna Ludovica Fracanzani, Sven Francque, Bradley Freilich, Juan Frias, Michael Fuchs, Javier Fuentes, Michael Galambos, Juan Gallegos, Anja Geerts, Jacob George, Maged Ghali, Reem Ghalib, Pierre Gholam, Pere Gines, Norman Gitlin, Tobias Goeser, John Goff, Stuart Gordon, Frederic Gordon, Odile Goria, Shaun Greer, Alla Grigorian, Henning Gronbaek, Maeva Guillaume, Naresh Gunaratnam, Dina Halegoua-De Marzio, Bilal Hameed, Stephanie Hametner, James Hamilton, Marek Hartleb, Tarek Hassanein, Dieter Häussinger, Paul Hellstern, Robert Herring, Eva Heurich, Christophe Hezode, Holger Hinrichsen, Peter Holland Fischer, Yves Horsmans, Jonathan Huang, Hyder Hussaini, Antoine Jakiche, Lennox Jeffers, Blake Jones, Rosa Jorge, Francisco Jorquera, Shoba Joshi, Alisan Kahraman, Kelly Kaita, Nicholas Karyotakis, Zeid Kayali, Stergios Kechagias, Thomas Kepczyk, Mandana Khalili, Hicham Khallafi, Johannes Kluwe, Anita Kohli, Kevin Korenblat, Kris Kowdley, Aleksander Krag, Richard Krause, Andreas Kremer, Karen Krok, Miodrag Krstic, Marcelo Kugelmas, Sonal Kumar, Scott Kuwada, Damien Labarriere, Michelle Lai, Wim Laleman, Pietro Lampertico, Alice Lee, Vincent Leroy, Steven Lidofsky, Tina Huey Lim, Joseph Lim, Donald Lipkis, Ester Little, Amadeo Lonardo, Michelle Long, Velimir Anthony Christopher Luketic, Yoav Lurie, Guilherme Macedo, Joana Magalhaes, Mihály Makara, Benedict Maliakkal, Michael Manns, Pinelopi Manousou, Parvez Mantry, Giulio Marchesini, Carla Marinho, Paul Marotta, Hanns-Ulrich Marschall, Linda Martinez, Marlyn Mayo, Mark McCullen, William McLaughlin, Uta Merle, Raphael Merriman, Apurva Modi, Esther Molina, Aldo Montano-Loza, Carlos Monteverde, Amilcar Morales Cardona, Sulleman Moreea, Christophe Moreno, Filomena Morisco, Abdullah Mubarak, Beat Muellhaupt, Sandeep Mukherjee, Tobias Müller, Aleksandar Nagorni, Jahnavi Naik, Guy Neff, Moises Nevah, Philip Newsome, Eric Nguyen-Khac, Mazen Noureddin, Jude Oben, Hans Orlent, James Orr, Grisell Ortiz-Lasanta, Violaine Ozenne, Prashant Pandya, Angelo Paredes, James Park, Joykumar Patel, Keyur Patel, Sonali Paul, Heather Patton, Markus Peck-Radosavljevic, Salvatore Petta, Stephen Pianko, Anna Piekarska, Neville Pimstone, Joseph Pisegna, Paul Pockros, Stanislas Pol, Michael Porayko, John Poulos, David Pound, Joe Pouzar, Jose Presa Ramos, Nikolaos Pyrsopoulos, Nila Rafiq, Kate Muller, Alnoor Ramji, Ravi Ravinuthala, Chakradhar Reddy, Gautham Reddy K G, K. Rajender Reddy K R, Frederic Regenstein, Robert Reindollar, Justin Reynolds, Andres Riera, Jose Rivera Acosta, Geert Robaeys, Stuart Roberts, Federico Rodriguez-Perez, Sandor Romero, Manuel Romero-Gomez, Raymond Rubin, Mariagrazia Rumi, Simon Rushbrook, Christian Rust, Michael Ryan, Rifaat Safadi, Adnan Said, Kimmo Salminen, Didier Samuel, John Santoro, Arun Sanyal, Souvik Sarkar, Cynthia Schaeffer, Jörn Schattenberg, Ingolf Schiefke, Eugene Schiff, Wolfgang Schmidt, Jeffrey Schneider, Jeoffrey Schouten, Michael Schultz, Giada Sebastiani, David Semela, Thomas Sepe, Aasim Sheikh, Muhammad Sheikh, Kenneth Sherman, Oren Shibolet, Mitchell Shiffman, Asma Siddique, Cyril Sieberhagen, Samuel Sigal, Katarzyna Sikorska, Krzysztof Simon, Marie Sinclair, Richard Skoien, Joel Solis, Siddharth Sood, Bob Souder, James Spivey, Per Stal, Laura Stinton, Simone Strasser, Petar Svorcan, Gyongzi Szabo, Andrew Talal, Edward Tam, Brent Tetri, Paul Thuluvath, Hillel Tobias, Krzysztof Tomasiewicz, Dawn Torres, Albert Tran, Michael Trauner, Christian Trautwein, Emanuel Tsochatzis, Esther Unitt, Victor Vargas, Istvan Varkonyi, Ella Veitsman, Umberto Vespasiani Gentilucci, David Victor, John Vierling, Catherine Vincent, Aron Vincze, Manfred von der Ohe, Natasha Von Roenn, Raj Vuppalanchi, Michael Waters, Kymberly Watt, Julia Wattacheril, Martin Weltman, Amanda Wieland, Gregory Wiener, Alonzo Williams A, Jeffrey Williams J, Jason Wilson, Maria Yataco, Eric Yoshida, Ziad Younes, Liyun Yuan, Adam Zivony, Donald Zogg, Heinz Zoller, Fabien Zoulim, Eli Zuckerman, Massimo Zuin, Younossi Z.M., Ratziu V., Loomba R., Rinella M., Anstee Q.M., Goodman Z., Bedossa P., Geier A., Beckebaum S., Newsome P.N., Sheridan D., Sheikh M.Y., Trotter J., Knapple W., Lawitz E., Abdelmalek M.F., Kowdley K.V., Montano-Loza A.J., Boursier J., Mathurin P., Bugianesi E., Mazzella G., Olveira A., Cortez-Pinto H., Graupera I., Orr D., Gluud L.L., Dufour J.-F., Shapiro D., Campagna J., Zaru L., MacConell L., Shringarpure R., Harrison S., Sanyal A.J., Abdelmalek M., Abrams G., Aguilar H., Ahmed A., Aigner E., Aithal G., Ala A., Alazawi W., Albillos A., Allison M., Al-Shamma S., Andrade R., Andreone P., Angelico M., Ankoma-Sey V., Anstee Q., Anty R., Araya V., Arenas Ruiz J.I., Arkkila P., Arora M., Asselah T., Au J., Ayonrinde O., Bailey R.J., Balakrishnan M., Bambha K., Bansal M., Barritt S., Bate J., Beato J., Behari J., Bellot P., Ben Ari Z., Bennett M., Berenguer M., Beretta-Piccoli B.T., Berg T., Bonacini M., Bonet L., Borg B., Bourliere M., Bowman W., Bradley D., Brankovic M., Braun M., Bronowicki J.-P., Bruno S., Cai C., Calleja Panero J.L., Carey E., Carmiel M., Carrion J.A., Cave M., Chagas C., Chami T., Chang A., Coates A., Cobbold J., Corey K., Corless L., Crespo J., Cruz Pereira O., de Ledinghen V., deLemos A., Diago M., Dugalic P., Dunn W., Elkhashab M., Epstein M., Escudero-Garcia M.D., Etzion O., Evans L., Falcone R., Fernandez C., Ferreira J., Fink S., Finnegan K., Firpi-Morell R., Floreani A., Fontanges T., Ford R., Forrest E., Fowell A., Fracanzani A.L., Francque S., Freilich B., Frias J., Fuchs M., Fuentes J., Galambos M., Gallegos J., Geerts A., George J., Ghali M., Ghalib R., Gholam P., Gines P., Gitlin N., Goeser T., Goff J., Gordon S., Gordon F., Goria O., Greer S., Grigorian A., Gronbaek H., Guillaume M., Gunaratnam N., Halegoua-De Marzio D., Hameed B., Hametner S., Hamilton J., Hartleb M., Hassanein T., Haussinger D., Hellstern P., Herring R., Heurich E., Hezode C., Hinrichsen H., Holland Fischer P., Horsmans Y., Huang J., Jakiche A., Jeffers L., Jones B., Jorge R., Jorquera F., Kahraman A., Kaita K., Karyotakis N., Kayali Z., Kechagias S., Kepczyk T., Khalili M., Khallafi H., Kluwe J., Kohli A., Korenblat K., Kowdley K., Krag A., Krause R., Kremer A., Krok K., Krstic M., Kugelmas M., Kumar S., Labarriere D., Lai M., Lampertico P., Lee A., Leroy V., Lidofsky S., Lim T.H., Lim J., Lipkis D., Little E., Lonardo A., Long M., Lurie Y., Macedo G., Makara M., Maliakkal B., Manns M., Manousou P., Mantry P., Marchesini G., Marinho C., Marotta P., Marschall H.-U., Mayo M., McCullen M., McLaughlin W., Merriman R., Modi A., Molina E., Montano-Loza A., Monteverde C., Moreea S., Moreno C., Morisco F., Mubarak A., Muellhaupt B., Mukherjee S., Muller T., Nagorni A., Naik J., Neff G., Nevah M., Newsome P., Nguyen-Khac E., Noureddin M., Oben J., Orlent H., Orr J., Ortiz-Lasanta G., Ozenne V., Pandya P., Paredes A., Park J., Patel J., Patel K., Uta M., Patton H., Peck-Radosavljevic M., Petta S., Pianko S., Piekarska A., Pimstone N., Pockros P., Pol S., Porayko M., Poulos J., Pound D., Pouzar J., Presa Ramos J., Pyrsopoulos N., Rafiq N., Muller K., Ramji A., Ravinuthala R., Reddy C., Reddy K G G., Reddy K R K.R., Regenstein F., Reindollar R., Riera A., Rivera Acosta J., Robaeys G., Roberts S., Rodriguez-Perez F., Romero-Gomez M., Rubin R., Rumi M., Rushbrook S., Rust C., Ryan M., Safadi R., Said A., Salminen K., Samuel D., Santoro J., Sanyal A., Sarkar S., Schaeffer C., Schattenberg J., Schiefke I., Schiff E., Schmidt W., Schneider J., Schouten J., Schultz M., Sebastiani G., Semela D., Sepe T., Sheikh A., Sheikh M., Sherman K., Shibolet O., Shiffman M., Siddique A., Sieberhagen C., Sigal S., Sikorska K., Simon K., Sinclair M., Skoien R., Solis J., Sood S., Souder B., Spivey J., Stal P., Stinton L., Strasser S., Svorcan P., Szabo G., Talal A., Tam E., Tetri B., Thuluvath P., Tobias H., Tomasiewicz K., Torres D., Trauner M., Trautwein C., Tsochatzis E., Unitt E., Vargas V., Varkonyi I., Veitsman E., Vespasiani Gentilucci U., Victor D., Vierling J., Vincent C., Vincze A., von der Ohe M., Von Roenn N., Vuppalanchi R., Waters M., Watt K., Weltman M., Wieland A., Wiener G., Williams A A., Williams J J., Wilson J., Yataco M., Yoshida E., Younes Z., Yuan L., Zivony A., Zogg D., Zoller H., Zoulim F., Zuckerman E., Zuin M., Repositório da Universidade de Lisboa, Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., Sheridan, D., Sheikh, M. Y., Trotter, J., Knapple, W., Lawitz, E., Abdelmalek, M. F., Kowdley, K. V., Montano-Loza, A. J., Boursier, J., Mathurin, P., Bugianesi, E., Mazzella, G., Olveira, A., Cortez-Pinto, H., Graupera, I., Orr, D., Gluud, L. L., Dufour, J. -F., Shapiro, D., Campagna, J., Zaru, L., Macconell, L., Shringarpure, R., Harrison, S., Sanyal, A. J., Abdelmalek, M., Abrams, G., Aguilar, H., Ahmed, A., Aigner, E., Aithal, G., Ala, A., Alazawi, W., Albillos, A., Allison, M., Al-Shamma, S., Andrade, R., Andreone, P., Angelico, M., Ankoma-Sey, V., Anstee, Q., Anty, R., Araya, V., Arenas Ruiz, J. I., Arkkila, P., Arora, M., Asselah, T., Au, J., Ayonrinde, O., Bailey, R. J., Balakrishnan, M., Bambha, K., Bansal, M., Barritt, S., Bate, J., Beato, J., Behari, J., Bellot, P., Ben Ari, Z., Bennett, M., Berenguer, M., Beretta-Piccoli, B. T., Berg, T., Bonacini, M., Bonet, L., Borg, B., Bourliere, M., Bowman, W., Bradley, D., Brankovic, M., Braun, M., Bronowicki, J. -P., Bruno, S., Cai, C., Calleja Panero, J. L., Carey, E., Carmiel, M., Carrion, J. A., Cave, M., Chagas, C., Chami, T., Chang, A., Coates, A., Cobbold, J., Corey, K., Corless, L., Crespo, J., Cruz Pereira, O., de Ledinghen, V., Delemos, A., Diago, M., Dugalic, P., Dunn, W., Elkhashab, M., Epstein, M., Escudero-Garcia, M. D., Etzion, O., Evans, L., Falcone, R., Fernandez, C., Ferreira, J., Fink, S., Finnegan, K., Firpi-Morell, R., Floreani, A., Fontanges, T., Ford, R., Forrest, E., Fowell, A., Fracanzani, A. L., Francque, S., Freilich, B., Frias, J., Fuchs, M., Fuentes, J., Galambos, M., Gallegos, J., Geerts, A., George, J., Ghali, M., Ghalib, R., Gholam, P., Gines, P., Gitlin, N., Goeser, T., Goff, J., Gordon, S., Gordon, F., Goria, O., Greer, S., Grigorian, A., Gronbaek, H., Guillaume, M., Gunaratnam, N., Halegoua-De Marzio, D., Hameed, B., Hametner, S., Hamilton, J., Hartleb, M., Hassanein, T., Haussinger, D., Hellstern, P., Herring, R., Heurich, E., Hezode, C., Hinrichsen, H., Holland Fischer, P., Horsmans, Y., Huang, J., Jakiche, A., Jeffers, L., Jones, B., Jorge, R., Jorquera, F., Kahraman, A., Kaita, K., Karyotakis, N., Kayali, Z., Kechagias, S., Kepczyk, T., Khalili, M., Khallafi, H., Kluwe, J., Kohli, A., Korenblat, K., Kowdley, K., Krag, A., Krause, R., Kremer, A., Krok, K., Krstic, M., Kugelmas, M., Kumar, S., Labarriere, D., Lai, M., Lampertico, P., Lee, A., Leroy, V., Lidofsky, S., Lim, T. H., Lim, J., Lipkis, D., Little, E., Lonardo, A., Long, M., Lurie, Y., Macedo, G., Makara, M., Maliakkal, B., Manns, M., Manousou, P., Mantry, P., Marchesini, G., Marinho, C., Marotta, P., Marschall, H. -U., Mayo, M., Mccullen, M., Mclaughlin, W., Merriman, R., Modi, A., Molina, E., Montano-Loza, A., Monteverde, C., Moreea, S., Moreno, C., Morisco, F., Mubarak, A., Muellhaupt, B., Mukherjee, S., Muller, T., Nagorni, A., Naik, J., Neff, G., Nevah, M., Newsome, P., Nguyen-Khac, E., Noureddin, M., Oben, J., Orlent, H., Orr, J., Ortiz-Lasanta, G., Ozenne, V., Pandya, P., Paredes, A., Park, J., Patel, J., Patel, K., Uta, M., Patton, H., Peck-Radosavljevic, M., Petta, S., Pianko, S., Piekarska, A., Pimstone, N., Pockros, P., Pol, S., Porayko, M., Poulos, J., Pound, D., Pouzar, J., Presa Ramos, J., Pyrsopoulos, N., Rafiq, N., Muller, K., Ramji, A., Ravinuthala, R., Reddy, C., Reddy K G, G., Reddy K R, K. R., Regenstein, F., Reindollar, R., Riera, A., Rivera Acosta, J., Robaeys, G., Roberts, S., Rodriguez-Perez, F., Romero-Gomez, M., Rubin, R., Rumi, M., Rushbrook, S., Rust, C., Ryan, M., Safadi, R., Said, A., Salminen, K., Samuel, D., Santoro, J., Sanyal, A., Sarkar, S., Schaeffer, C., Schattenberg, J., Schiefke, I., Schiff, E., Schmidt, W., Schneider, J., Schouten, J., Schultz, M., Sebastiani, G., Semela, D., Sepe, T., Sheikh, A., Sheikh, M., Sherman, K., Shibolet, O., Shiffman, M., Siddique, A., Sieberhagen, C., Sigal, S., Sikorska, K., Simon, K., Sinclair, M., Skoien, R., Solis, J., Sood, S., Souder, B., Spivey, J., Stal, P., Stinton, L., Strasser, S., Svorcan, P., Szabo, G., Talal, A., Tam, E., Tetri, B., Thuluvath, P., Tobias, H., Tomasiewicz, K., Torres, D., Trauner, M., Trautwein, C., Tsochatzis, E., Unitt, E., Vargas, V., Varkonyi, I., Veitsman, E., Vespasiani Gentilucci, U., Victor, D., Vierling, J., Vincent, C., Vincze, A., von der Ohe, M., Von Roenn, N., Vuppalanchi, R., Waters, M., Watt, K., Weltman, M., Wieland, A., Wiener, G., Williams A, A., Williams J, J., Wilson, J., Yataco, M., Yoshida, E., Younes, Z., Yuan, L., Zivony, A., Zogg, D., Zoller, H., Zoulim, F., Zuckerman, E., Zuin, M., Younossi, Zobair M, Ratziu, Vlad, Loomba, Rohit, Rinella, Mary, Anstee, Quentin M, Goodman, Zachary, Bedossa, Pierre, Geier, Andrea, Beckebaum, Susanne, Newsome, Philip N, Sheridan, David, Sheikh, Muhammad Y, Trotter, Jame, Knapple, Whitfield, Lawitz, Eric, Abdelmalek, Manal F, Kowdley, Kris V, Montano-Loza, Aldo J, Boursier, Jerome, Mathurin, Philippe, Bugianesi, Elisabetta, Mazzella, Giuseppe, Olveira, Antonio, Cortez-Pinto, Helena, Graupera, Isabel, Orr, David, Gluud, Lise Lotte, Dufour, Jean-Francoi, Shapiro, David, Campagna, Jason, Zaru, Luna, MacConell, Leigh, Shringarpure, Reshma, Harrison, Stephen, Sanyal, Arun J, Abdelmalek, Manal, Abrams, Gary, Aguilar, Humberto, Ahmed, Aijaz, Aigner, Elmar, Aithal, Guruprasad, Ala, Aftab, Alazawi, William, Albillos, Agustin, Allison, Michael, Al-Shamma, Sfa, Andrade, Raul, Andreone, Pietro, Angelico, Mario, Ankoma-Sey, Victor, Anstee, Quentin, Anty, Rodolphe, Araya, Victor, Arenas Ruiz, Juan Ignacio, Arkkila, Perttu, Arora, Marty, Asselah, Tarik, Au, Jennifer, Ayonrinde, Oyekoya, Bailey, Robert Jame, Balakrishnan, Maya, Bambha, Kiran, Bansal, Meena, Barritt, Sidney, Bate, John, Beato, Jorge, Behari, Jaideep, Bellot, Pablo, Ben Ari, Ziv, Bennett, Michael, Berenguer, Marina, Beretta-Piccoli, Benedetta Terziroli, Berg, Thoma, Bonacini, Maurizio, Bonet, Lucia, Borg, Brian, Bourliere, Marc, Bowman, William, Bradley, David, Brankovic, Marija, Braun, Mariu, Bronowicki, Jean-Pierre, Bruno, Savino, Cai, Cindy, Calleja Panero, José Lui, Carey, Elizabeth, Carmiel, Michal, Carrión, Jose Antonio, Cave, Matthew, Chagas, Cristina, Chami, Tawfik, Chang, Alan, Coates, Allan, Cobbold, Jeremy, Corey, Kathleen, Corless, Lynsey, Crespo, Javier, Cruz Pereira, Oscar, de Ledinghen, Victor, deLemos, Andrew, Diago, Moise, Dufour, Jean-Françoi, Dugalic, Predrag, Dunn, Winston, Elkhashab, Magby, Epstein, Michael, Escudero-Garcia, Maria Desamparado, Etzion, Ohad, Evans, Larry, Falcone, Robert, Fernandez, Conrado, Ferreira, Jose, Fink, Scott, Finnegan, Kevin, Firpi-Morell, Roberto, Floreani, Annarosa, Fontanges, Thierry, Ford, Ryan, Forrest, Ewan, Fowell, Andrew, Fracanzani, Anna Ludovica, Francque, Sven, Freilich, Bradley, Frias, Juan, Fuchs, Michael, Fuentes, Javier, Galambos, Michael, Gallegos, Juan, Geerts, Anja, George, Jacob, Ghali, Maged, Ghalib, Reem, Gholam, Pierre, Gines, Pere, Gitlin, Norman, Goeser, Tobia, Goff, John, Gordon, Stuart, Gordon, Frederic, Goria, Odile, Greer, Shaun, Grigorian, Alla, Gronbaek, Henning, Guillaume, Maeva, Gunaratnam, Naresh, Halegoua-De Marzio, Dina, Hameed, Bilal, Hametner, Stephanie, Hamilton, Jame, Hartleb, Marek, Hassanein, Tarek, Häussinger, Dieter, Hellstern, Paul, Herring, Robert, Heurich, Eva, Hezode, Christophe, Hinrichsen, Holger, Holland Fischer, Peter, Horsmans, Yve, Huang, Jonathan, Jakiche, Antoine, Jeffers, Lennox, Jones, Blake, Jorge, Rosa, Jorquera, Francisco, Kahraman, Alisan, Kaita, Kelly, Karyotakis, Nichola, Kayali, Zeid, Kechagias, Stergio, Kepczyk, Thoma, Khalili, Mandana, Khallafi, Hicham, Kluwe, Johanne, Kohli, Anita, Korenblat, Kevin, Kowdley, Kri, Krag, Aleksander, Krause, Richard, Kremer, Andrea, Krok, Karen, Krstic, Miodrag, Kugelmas, Marcelo, Kumar, Sonal, Labarriere, Damien, Lai, Michelle, Lampertico, Pietro, Lee, Alice, Leroy, Vincent, Lidofsky, Steven, Lim, Tina Huey, Lim, Joseph, Lipkis, Donald, Little, Ester, Lonardo, Amadeo, Long, Michelle, Lurie, Yoav, Macedo, Guilherme, Makara, Mihály, Maliakkal, Benedict, Manns, Michael, Manousou, Pinelopi, Mantry, Parvez, Marchesini, Giulio, Marinho, Carla, Marotta, Paul, Marschall, Hanns-Ulrich, Mayo, Marlyn, McCullen, Mark, McLaughlin, William, Merriman, Raphael, Modi, Apurva, Molina, Esther, Montano-Loza, Aldo, Monteverde, Carlo, Moreea, Sulleman, Moreno, Christophe, Morisco, Filomena, Mubarak, Abdullah, Muellhaupt, Beat, Mukherjee, Sandeep, Müller, Tobia, Nagorni, Aleksandar, Naik, Jahnavi, Neff, Guy, Nevah, Moise, Newsome, Philip, Nguyen-Khac, Eric, Noureddin, Mazen, Oben, Jude, Orlent, Han, Orr, Jame, Ortiz-Lasanta, Grisell, Ozenne, Violaine, Pandya, Prashant, Paredes, Angelo, Park, Jame, Patel, Joykumar, Patel, Keyur, Uta, Merle, Patton, Heather, Peck-Radosavljevic, Marku, Petta, Salvatore, Pianko, Stephen, Piekarska, Anna, Pimstone, Neville, Pockros, Paul, Pol, Stanisla, Porayko, Michael, Poulos, John, Pound, David, Pouzar, Joe, Presa Ramos, Jose, Pyrsopoulos, Nikolao, Rafiq, Nila, Muller, Kate, Ramji, Alnoor, Ravinuthala, Ravi, Reddy, Chakradhar, Reddy K G, Gautham, Reddy K R, K. Rajender, Regenstein, Frederic, Reindollar, Robert, Riera, Andre, Rivera Acosta, Jose, Robaeys, Geert, Roberts, Stuart, Rodriguez-Perez, Federico, Romero-Gomez, Manuel, Rubin, Raymond, Rumi, Mariagrazia, Rushbrook, Simon, Rust, Christian, Ryan, Michael, Safadi, Rifaat, Said, Adnan, Salminen, Kimmo, Samuel, Didier, Santoro, John, Sanyal, Arun, Sarkar, Souvik, Schaeffer, Cynthia, Schattenberg, Jörn, Schiefke, Ingolf, Schiff, Eugene, Schmidt, Wolfgang, Schneider, Jeffrey, Schouten, Jeoffrey, Schultz, Michael, Sebastiani, Giada, Semela, David, Sepe, Thoma, Sheikh, Aasim, Sheikh, Muhammad, Sherman, Kenneth, Shibolet, Oren, Shiffman, Mitchell, Siddique, Asma, Sieberhagen, Cyril, Sigal, Samuel, Sikorska, Katarzyna, Simon, Krzysztof, Sinclair, Marie, Skoien, Richard, Solis, Joel, Sood, Siddharth, Souder, Bob, Spivey, Jame, Stal, Per, Stinton, Laura, Strasser, Simone, Svorcan, Petar, Szabo, Gyongzi, Talal, Andrew, Tam, Edward, Tetri, Brent, Thuluvath, Paul, Tobias, Hillel, Tomasiewicz, Krzysztof, Torres, Dawn, Trauner, Michael, Trautwein, Christian, Tsochatzis, Emanuel, Unitt, Esther, Vargas, Victor, Varkonyi, Istvan, Veitsman, Ella, Vespasiani Gentilucci, Umberto, Victor, David, Vierling, John, Vincent, Catherine, Vincze, Aron, von der Ohe, Manfred, Von Roenn, Natasha, Vuppalanchi, Raj, Waters, Michael, Watt, Kymberly, Weltman, Martin, Wieland, Amanda, Wiener, Gregory, Williams A, Alonzo, Williams J, Jeffrey, Wilson, Jason, Yataco, Maria, Yoshida, Eric, Younes, Ziad, Yuan, Liyun, Zivony, Adam, Zogg, Donald, Zoller, Heinz, Zoulim, Fabien, Zuckerman, Eli, Zuin, Massimo, and REGENERATE Study Investigators
- Subjects
Male ,Biopsy ,Clinical Trial, Phase III ,Administration, Oral ,030204 cardiovascular system & hematology ,Chronic liver disease ,Settore MED/04 ,Biomarkers/analysis ,Gastroenterology ,chemistry.chemical_compound ,0302 clinical medicine ,Liver Function Tests ,Non-alcoholic Fatty Liver Disease ,Clinical endpoint ,Medicine ,030212 general & internal medicine ,610 Medicine & health ,Chenodeoxycholic Acid/administration & dosage ,education.field_of_study ,Liver Function Test ,Research Support, Non-U.S. Gov't ,Fatty liver ,Obeticholic acid ,NASH, OBETICHOLIC ACID ,General Medicine ,Middle Aged ,Multicenter Study ,Randomized Controlled Trial ,Administration ,Female ,Biomarkers ,Chenodeoxycholic Acid ,Double-Blind Method ,Humans ,Human ,Oral ,medicine.medical_specialty ,Population ,Placebo ,03 medical and health sciences ,Research Support, N.I.H., Extramural ,Internal medicine ,Journal Article ,education ,Intention-to-treat analysis ,business.industry ,Biomarker ,Interim analysis ,medicine.disease ,Non-alcoholic Fatty Liver Disease/drug therapy ,chemistry ,Human medicine ,business - Abstract
© 2019 Elsevier Ltd. All rights reserved., Background: Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods: In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH, non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2-F3, or F1 with at least one accompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpoints for the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2-F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6. Findings: Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1-F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2-F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1-F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). Interpretation: Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes.
- Published
- 2019
- Full Text
- View/download PDF
148. The HLA-DQβ1 insertion is a strong achalasia risk factor and displays a geospatial north-south gradient among Europeans
- Author
-
Justyna Wasielica-Berger, Giovanni Sarnelli, Antonio Ruiz de León, Michael Vieth, Anders Thorell, Magdalena Gawron-Kiszka, Michaela Müller, Andrzej Dąbrowski, Per Hall, Jonna Bister, V. Annese, Markus M. Nöthen, Burkhard H.A. von Rahden, Magnus Nilsson, Guy E. Boeckxstaens, Anna Mokrowiecka, Cisca Wijmenga, Julio Perez de la Serna, Leszek Paradowski, Marek L. Kowalski, Henning G. Schulz, Uberto Fumagalli, Tomasz Marek, Marek Majewski, Stephan L. Haas, Johannes Schumacher, Agata Mulak, Srdjan Kostic, Riccardo Rosati, Grzegorz Wallner, Till Schwämmle, Lothar Veits, Marek Hartleb, Zeeshan Ateeb, Michael Knapp, Jessica Becker, Anna Latiano, Paul I.W. de Bakker, Ines Gockel, Stefan Niebisch, Elena Urcelay, Krystian Adrych, Mats Lindblad, Frank Lenze, Hauke Lang, Anita Gąsiorowska, Ewa Małecka-Panas, Luigi Laghi, Mira M. Wouters, Timo Hess, Maria Janiak, Anna Dziurkowska-Marek, Peter Elbe, Rosario Cuomo, Jose Luis Santiago, Kamila Czene, Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Department of Health and Life Sciences, Becker, Jessica, Haas, Stephan L, Mokrowiecka, Anna, Wasielica Berger, Justyna, Ateeb, Zeeshan, Bister, Jonna, Elbe, Peter, Kowalski, Marek, Gawron Kiszka, Magdalena, Majewski, Marek, Mulak, Agata, Janiak, Maria, Wouters, Mira M, Schwämmle, Till, Hess, Timo, Veits, Lothar, Niebisch, Stefan, Santiago, José L, de León, Antonio Ruiz, de la Serna, Julio Pérez, Urcelay, Elena, Annese, Vito, Latiano, Anna, Fumagalli, Uberto, Rosati, Riccardo, Laghi, Luigi, Cuomo, Rosario, Lenze, Frank, Sarnelli, Giovanni, Müller, Michaela, von Rahden, Burkhard HA, Wijmenga, Cisca, Lang, Hauke, Czene, Kamila, Hall, Per, de Bakker, Paul IW, Vieth, Michael, Nöthen, Markus M, Schulz, Henning G, Adrych, Krystian, Gąsiorowska, Anita, Paradowski, Leszek, Wallner, Grzegorz, Boeckxstaens, Guy E, Gockel, Ine, Hartleb, Marek, Kostic, Srdjan, Dziurkowska Marek, Anna, Lindblad, Mat, Nilsson, Magnu, Knapp, Michael, Thorell, Ander, Marek, Tomasz, Dąbrowski, Andrzej, Małecka Panas, Ewa, Schumacher, Johannes, Schumacher, J, Becker, J, Haas, S, Mokrowiecka, A, Wasielica Berger, J, Ateeb, Z, Bister, J, Elbe, P, Kowalski, M, Gawron Kiszka, M, Majewski, M, Mulak, A, Janiak, M, Wouters, M, Schwämmle, T, Hess, T, Veits, L, Niebisch, S, Santiago, Jl, Ruiz de León, A, Pérez de la Serna, J, Urcelay, E, Annese, V, Latiano, A, Fumagalli, U, Laghi, L, Cuomo, R, Lenze, F, Sarnelli, G, Müller, M, von Rahden, B, Wijmenga, C, Lang, H, Czene, K, Hall, P, de Bakker, P, Vieth, M, Nöthen, M, Schulz, H, Adrych, K, Gąsiorowska, A, Paradowski, L, Wallner, G, Boeckxstaens, G, Gockel, I, Hartleb, M, Kostic, S, Dziurkowska Marek, A, Lindblad, Nilsson, M, Knapp, M, Thorell, A, Marek, T, Dąbrowski, A, and Małecka Panas, E.
- Subjects
0301 basic medicine ,Male ,European Continental Ancestry Group ,Short Report ,Achalasia ,Human leukocyte antigen ,White People ,03 medical and health sciences ,0302 clinical medicine ,Swedish population ,Genetic ,Genetics, esophageal achalasia ,Mutation Rate ,Genetics ,medicine ,otorhinolaryngologic diseases ,Prevalence ,HLA-DQ beta-Chains ,Humans ,In patient ,Esophagus ,Risk factor ,Genetics (clinical) ,HLA-DQ beta-Chain ,Polymorphism, Genetic ,business.industry ,European population ,medicine.disease ,Esophageal Achalasia ,Europe ,Mutagenesis, Insertional ,030104 developmental biology ,medicine.anatomical_structure ,Attributable risk ,030211 gastroenterology & hepatology ,Female ,business ,Human ,Demography - Abstract
Idiopathic achalasia is a severe motility disorder of the esophagus and is characterized by a failure of the lower esophageal sphincter to relax due to a loss of neurons in the myenteric plexus. Most recently, we identified an eight-amino-acid insertion in the cytoplasmic tail of HLA-DQβ1 as strong achalasia risk factor in a sample set from Central Europe, Italy and Spain. Here, we tested whether the HLA-DQβ1 insertion also confers achalasia risk in the Polish and Swedish population. We could replicate the initial findings and the insertion shows strong achalasia association in both samples (Poland P=1.84 × 10(-04), Sweden P=7.44 × 10(-05)). Combining all five European data sets - Central Europe, Italy, Spain, Poland and Sweden - the insertion is achalasia associated with Pcombined=1.67 × 10(-35). In addition, we observe that the frequency of the insertion shows a geospatial north-south gradient. The insertion is less common in northern (around 6-7% in patients and 2% in controls from Sweden and Poland) compared with southern Europeans (~16% in patients and 8% in controls from Italy) and shows a stronger attributable risk in the southern European population. Our study provides evidence that the prevalence of achalasia may differ between populations.European Journal of Human Genetics advance online publication, 6 January 2016; doi:10.1038/ejhg.2015.262. ispartof: European Journal of Human Genetics vol:24 issue:8 pages:1228-1231 ispartof: location:England status: published
- Published
- 2016
149. The prospective validation of a scoring system to assess mucosal cleanliness during EGD.
- Author
-
Romańczyk M, Ostrowski B, Lesińska M, Wieszczy-Szczepanik P, Pawlak KM, Kurek K, Wrońska E, Kozłowska-Petriczko K, Waluga M, Romańczyk T, Wosiewicz P, Bugajski M, Hartleb M, Kamiński MF, and Sharma P
- Subjects
- Humans, Male, Female, Middle Aged, Prospective Studies, Aged, Gastric Mucosa pathology, Intestinal Mucosa pathology, Adult, Esophageal Mucosa pathology, Duodenum pathology, Endoscopy, Digestive System methods
- Abstract
Background and Aims: Cleanliness of the mucosa of the upper GI (UGI) tract is critical for performing a high-quality EGD. The aim of this study was to validate a recently developed UGI cleanliness scale (the Polprep: Effective Assessment of Cleanliness in Esophagogastroduodenoscopy [PEACE] system) in the detection of clinically significant lesions (CSLs) in the UGI tract., Methods: Patients who underwent a complete diagnostic EGD were prospectively enrolled from August 2021 to October 2022. The UGI tract (esophagus, stomach, and duodenum) cleanliness was scored from 0 to 3 for each segment. The primary outcomes were the detection of CSLs and PEACE scores., Results: Of 995 patients enrolled from 5 centers, adequate cleanliness (AQ; all scores ≥2) was found in 929 patients. In multivariate regression analysis, AQ was associated with the number of diagnosed CSLs (odds ratio [OR], 1.78; 95% confidence interval [CI], 1.06-3.01; P = .03). Other factors related to CSL detection were duration of EGD (OR, 1.29, 95% CI, 1.23-1.35, P < .001), male sex (OR, 1.33, 95% CI, 1.04-1.71; P = .025), and EGD indication (dyspepsia, alarm symptoms, gastritis surveillance, other indications vs GERD) (OR, 0.43 [95% CI, 0.31-0.6, P < .001], OR, 0.44 [95% CI, 0.28-0.67, P < .001], OR, 0.44 [95% CI, 0.25-0.76; P = .004], and OR, 0.44 [95% CI, 0.31-0.62; P < .001], respectively). Twenty-seven patients were diagnosed with UGI neoplasia, all in patients with adequate cleanliness of the UGI tract., Conclusions: Adequate cleanliness of the UGI tract as assessed with the PEACE system was associated with a significantly higher detection rate of CSLs during EGD. The relationship of this scale with UGI neoplasia detection warrants further investigation., Competing Interests: Disclosure The following authors disclosed financial relationships: P. Sharma: consultant for Boston Scientific, Olympus, Salix Pharmaceuticals, Cipla, Medtronic, Takeda, Samsung Bioepis, and CDx; grant support from ERBE and Fujifilm. M. F. Kamiński: consultant for Olympus and Erbe; speaker for Boston Scientific, Ipsen, and Recordati; grant support from Olympus. All of the other authors disclosed no financial relationships., (Copyright © 2024 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
150. Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity: study protocol of a randomized, double-blind, phase IV clinical trial.
- Author
-
Stefan N, Hartleb M, Popovic B, and Varona R
- Subjects
- Humans, Double-Blind Method, Treatment Outcome, Phospholipids, Clinical Trials, Phase IV as Topic, Male, Adult, Female, Middle Aged, Diabetes Mellitus, Type 2 complications, Obesity complications, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Quality of Life, Fatty Liver, Hyperlipidemias complications
- Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a predominant chronic liver condition globally and is strongly associated with obesity, diabetes mellitus, and dyslipidemia. Essential phospholipids (EPL) are recommended as supportive treatment for managing liver conditions, including MASLD or metabolic dysfunction-associated steatohepatitis, cirrhosis, and viral hepatitis. While efficacy of EPL as an adjunctive therapy in MASLD treatment has been established earlier, certain aspects of its usage such as the impact of standard-of-care parameters, effect of EPL on quality of life (QoL) and change in symptoms evaluation in patients with MASLD remain unexplored. The proposed trial aims to assess the efficacy and safety of EPL and the subsequent QoL of patients with MASLD associated with type 2 diabetes mellitus (T2DM) and/or hyperlipidemia and/or obesity., Methods: This is a multicenter, multinational, double-blind, randomized, two-arm, placebo-controlled, parallel-group, phase IV clinical trial. The trial is being conducted in approximately 190 patients who are randomized on a 1:1 basis either to the EPL arm (Essentiale® 1800 mg/day orally + standard of care) or placebo arm (placebo + standard of care). The primary outcome is to assess the efficacy of EPL on hepatic steatosis, as measured by transient elastography, from baseline to 6 months. The secondary outcomes include change in QoL parameters, as measured by the Chronic Liver Disease Questionnaire-metabolic dysfunction-associated steatotic liver disease/ metabolic dysfunction-associated steatohepatitis and change in symptom evaluation (using the Global Overall Symptom scale) from baseline to 6 months for symptoms, including asthenia, feeling depressed, abdominal pain/discomfort, or fatigue., Discussion: The current protocol design will allow to comprehensively explore the efficacy of EPL added to the standard of care on hepatic steatosis and QoL and its safety in patients with MASLD associated with T2DM and/or hyperlipidemia and/or obesity by assessing various outcome measures., Trial Registration: European Union Clinical Trials Register, EudraCT, 2021-006069-39. Registered on March 13, 2022., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.